Chimerix Investor Presentation Deck
May 2023, 41 slides
  1. Chimerix
  2. Related Decks
  3. Investor Presentation Decks
corporate presentation | Chimerix
forward looking statements this presentation contains forward looking statements within the meaning of the private securities litigation reform act of that are subject to risks and uncertainties that could cause actual results to differ materially from those projected forward looking statements include those relating to among other things the probability of success of the phase action study the potential filing and approval of an for and subsequent commercial opportunity the implications of the radiographic partial response observed during dose the ability to reproduce clinical and clinical findings and projections regarding funding and timing of future data among the factors and risks that could cause actual results to differ materially from those indicated in the forward looking statements are risks related to the timing completion and outcome of the phase action study of risks associated with repeating positive results obtained in prior preclinical or clinical studies in future studies risks related to the clinical development of and additional risks set forth in the company filings with the securities and exchange commission these forward looking statements represent the company judgment as of the date of this release the company disclaims however any intent or obligation to update these forward looking statements | Chimerix
investment highlights | Chimerix
deep pipeline across all development stages | Chimerix
phase efficacy analysis | Chimerix
mutant diffuse glioma high unmet need recurrent | Chimerix
phase efficacy for in recurrent | Chimerix
aligned criteria for phase efficacy analysis to isolate single agent activity eligibility | Chimerix
waterfall plot response disease control | Chimerix
responses observed across age groups a a nan | Chimerix
response correlation to performance status supports early line trial mutant diffuse glioma a minas | Chimerix
clinically meaningful and durable responses | Chimerix
safety a | Chimerix
responses correspond with survival clinical benefit response strongly at months | Chimerix
strong rationale for phase success relative to recent trials yes no | Chimerix
phase action study summary | Chimerix
pivotal phase action trial design primary overall survival day | Chimerix
multiple unique aspects to data support translation to phase success | Chimerix
design provides multiple paths for success | Chimerix
potential to increase efficacy with dose schedule therapeutic exposure | Chimerix
market opportunity assessment | Chimerix
mutant glioma rapid ramp to peak revenue expected | Chimerix
regulatory designations | Chimerix
interim efficacy results in secreting tumors outside the brain | Chimerix
mechanism of action | Chimerix
directly engages and ewe antagonism | Chimerix
glioma primed for sensitivity | Chimerix
central characteristic reversed by i | Chimerix
| Chimerix
oral brain penetrant antagonist agonist | Chimerix
active in models of and other cancers ovarian cancer | Chimerix
dose intensification expected to enhance therapeutic exposure consecutive day dosing may increase incubation time | Chimerix
dose pediatric and adult tumors | Chimerix
new cases of annually in the top markets market opportunity out | Chimerix
preclinical development and | Chimerix
agonist | Chimerix
anti preclinical activity that is a viral inhibitor replicating | Chimerix
corporate update | Chimerix
deal term summary emergent is an experienced company collaborating with government agencies to protect public health terms summary oral suspension tablets | Chimerix
financial strength supports development through key catalysts a | Chimerix
corporate presentation | Chimerix
See More
Chimerix
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Tumor
Cancer
Monotherapy
Recent decks by Chimerix
Investor Presentation
August 2023
Investor Presentation
March 2023
Results
March 2022
Investor Conference
November 2021
See all presentations by Chimerix (6 decks)
Related decks
Alkermes
Results
June 2021
CG Oncology
IPO
March 2024
BioAtla
Investor Presentation
August 2023
Alkermes
Results
June 2022
Immatics
Investor Presentation
November 2023
Fusion Pharmaceuticals
IPO
June 2020
BioAtla
Investor Presentation
November 2022
Immatics
Results
October 2022
Recent decks by Chimerix
See all presentations (6 decks)
Investor Presentation
August 2023
Investor Presentation
March 2023
Results
March 2022
Investor Conference
November 2021
Alkermes
Results
June 2021
CG Oncology
IPO
March 2024
BioAtla
Investor Presentation
August 2023
Alkermes
Results
June 2022
Immatics
Investor Presentation
November 2023
Fusion Pharmaceuticals
IPO
June 2020
BioAtla
Investor Presentation
November 2022
Immatics
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights